Scarica l'app Stockscreener
3.32
2.06%
-0.07
Dopo l'orario di chiusura:
3.30
-0.02
-0.60%
Prime Medicine Inc Borsa (PRME) Ultime notizie
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga
Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Prime Medicine slips after Q4 updates - MSN
Prime Medicine, Inc. (NASDAQ:PRME) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Sahm
Bear Alert: Should I trade or invest in Prime Medicine Inc2026 Bull vs Bear & Low Volatility Stock Recommendations - baoquankhu1.vn
S P Trends: Will Prime Medicine Inc stock hit new highs in YEARMarket Performance Summary & Precise Buy Zone Identification - baoquankhu1.vn
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3%What's Next? - MarketBeat
Prime Medicine (PRME) focuses on liver franchise with $191.4M cash runway - msn.com
Prime Medicine (NASDAQ:PRME) Trading Up 5.6%Time to Buy? - MarketBeat
Support Test: Does Prime Medicine Inc have declining or rising EPSWeekly Risk Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Aug PostEarnings: Is Prime Medicine Inc a strong growth stock2026 Trade Ideas & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Prime Medicine, Inc. (PRME) reports Q4 loss, misses revenue estimates - MSN
Hedge Fund Bets: Whats the fair value of Prime Medicine Inc stock2026 Institutional & Risk Managed Investment Entry Signals - baoquankhu1.vn
Farallon Capital Management LLC Buys 4,000,000 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Casdin Capital LLC Acquires 1,600,000 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Aug Weekly: Is Prime Medicine Inc backed by strong institutional buyingMarket Sentiment Review & Reliable Entry Point Alerts - baoquankhu1.vn
Oppenheimer Initiates Coverage on PRME with "Outperform" Rating - GuruFocus
Prime Medicine (NASDAQ:PRME) Shares Gap UpHere's Why - MarketBeat
Prime Medicine (NYSE:PRME) Shares Gap UpShould You Buy? - MarketBeat
Prime Medicine (NYSE:PRME) Earns Outperform Rating from Analysts at Oppenheimer - MarketBeat
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - MSN
Prime Medicine (NASDAQ:PRME) Trading Down 6.3%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Shares Down 6.9%Here's What Happened - MarketBeat
PRME Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway - Finviz
Will Prime Medicine Inc. stock outperform value stocksPrice Action & Technical Confirmation Alerts - Naître et grandir
Will Prime Medicine Inc. stock benefit from upcoming earnings reportsJuly 2025 Update & Growth Focused Entry Reports - Naître et grandir
10 Best New Penny Stocks to Buy - Insider Monkey
LifeSci Capital initiates Prime Medicine (PRME), highlights one-and-done potential in liver and lung diseases - MSN
Guidance Update: Will Prime Medicine Inc stock hit new highs in YEARPortfolio Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
HC Wainwright Predicts Stronger Earnings for Prime Medicine - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine, Inc. Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
Lifesci Capital Predicts Prime Medicine FY2025 Earnings - MarketBeat
Prime Medicine, Inc. $PRME Shares Acquired by ARK Investment Management LLC - MarketBeat
Prime Medicine, Inc. $PRME Stock Position Increased by Amova Asset Management Americas Inc. - MarketBeat
[EFFECT] Prime Medicine, Inc. SEC Filing - Stock Titan
Citizens reiterates Prime Medicine stock rating on PM359 pathway - Investing.com Australia
Citizens reiterates Prime Medicine stock rating on PM359 pathway By Investing.com - Investing.com Canada
Prime Medicine (NASDAQ:PRME) Upgraded by Lifesci Capital to "Strong-Buy" Rating - MarketBeat
Prime to test FDA flexibility with 2-patient gene editing submission - BioPharma Dive
Prime Medicine (PRME) Quarterly Loss Near US$50 Million Reinforces Bearish Community Narratives - simplywall.st
Prime Medicine unveils full year 2025 financial results and business update as progress advances - Traders Union
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates - Bitget
Prime Medicine Reports 2025 Results, Advances Gene Editing Pipeline - TipRanks
Prime Medicine 2025 Net Loss Narrows as Revenue Rises -- Shares Fall Pre-Bell - marketscreener.com
Earnings Flash (PRME) Prime Medicine Posts 2025 Total Revenue $4.6M, vs. FactSet Est of $5.7M - marketscreener.com
Earnings Flash (PRME) Prime Medicine Posts 2025 Net Loss $1.35 a Share, vs. FactSet Est of $1.30 Loss - marketscreener.com
Prime Medicine : March 2026 Corporate Presentation - marketscreener.com
Prime Medicine 2025 net loss widens, hurt by higher R&D expenses - TradingView
Prime Medicine (Nasdaq: PRME) details 2025 results, cash runway and gene-editing milestones - Stock Titan
PRME Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):